Study of Pembrolizumab and Olaparib in Bile Duct Cancer
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The investigators propose an open label, one-arm study to assess the safety and efficacy of
olaparib and pembrolizumab in patients with cholangiocarcinoma who have progressed on or
cannot tolerate gemcitabine-based therapy.